New York State Common Retirement Fund Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP)

New York State Common Retirement Fund bought a new stake in Rapport Therapeutics (NASDAQ:RAPP) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,500 shares of the company’s stock, valued at approximately $62,000.

Other large investors also recently bought and sold shares of the company. BNP Paribas Financial Markets acquired a new stake in shares of Rapport Therapeutics during the third quarter worth about $34,000. The Manufacturers Life Insurance Company increased its stake in shares of Rapport Therapeutics by 2.4% during the third quarter. The Manufacturers Life Insurance Company now owns 77,344 shares of the company’s stock worth $1,584,000 after buying an additional 1,828 shares during the period. Barclays PLC increased its stake in shares of Rapport Therapeutics by 36.8% during the third quarter. Barclays PLC now owns 12,863 shares of the company’s stock worth $264,000 after buying an additional 3,463 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of Rapport Therapeutics during the third quarter worth approximately $83,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of Rapport Therapeutics during the third quarter worth approximately $117,000.

Rapport Therapeutics Stock Performance

RAPP stock opened at $8.08 on Friday. The company’s 50 day moving average price is $14.63 and its 200 day moving average price is $19.26. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $29.74.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.